Eli Lilly & Co (NYSE:LLY) Presents a High Growth Momentum and Technical Breakout Opportunity Eli Lilly (LLY) is a top growth momentum stock with accelerating earnings, strong technical ratings, and a positive breakout setup for investors.
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the market. While specific daily performance metrics remain unreleased, today's trading likely saw the sector reacting to a
What Is 1 of the Best Pharmaceutical Stocks to Buy Now? This pharma giant is entering the rapidly expanding market for weight loss drugs.
Down 15%, Should You Buy the Dip on Eli Lilly? Lilly's stock has pulled back from its 2024 highs, but that doesn't mean the shares are cheap enough to buy.
Should You Buy Eli Lilly Stock Before Oct. 30? Long-term investors don't need to rush to buy Eli Lilly stock.
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? The clinical-stage biotech is working on a new type of weight management drug.
Eli Lilly And Co. Stock: Gains As $12.47-Per-Share Adverum Biotech Deal Expands Gene Therapy Portfolio Eli Lilly stock rises as $12.47-per-share Adverum Biotech deal boosts its gene therapy ambitions and expands ophthalmology pipeline.
Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth.
Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones.
Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears Eli Lilly jumps to top 10% in quality rankings, showing strong fundamentals even as Trump pushes for weight loss drug price cuts in 2025.
2 Vanguard ETFs to Buy With $1,000 and Hold Forever These exchange-traded funds could be great complementary additions to your portfolio.
WST Stock Soars After Company Raises Full-Year Guidance On Strong Demand For GLP-1 Drug Components The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.
Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies Viking Therapeutics stock popped Thursday on the lightening pace it's enrolling patients in a pair of obesity treatment tests.
Weight Loss Drugs Are Quietly Exploding Employer Health Insurance Costs: 'There Is A Quiet Alarm Bell Going Off' Employer-sponsored health insurance costs rise for third year, with average family premiums at $27,000 in 2025. Drug costs and GLP-1s drive spending.
